Bone Diseases
Diseases of BONES.
Subtype terms (23)
More specific conditions that are subtypes of Bone Diseases in the MeSH hierarchy.
- Bone Cysts
2 drugs (1 approved, 1 experimental)
- Bone Diseases, Developmental
2 drugs (1 approved, 1 experimental)
- Bone Diseases, Endocrine
4 drugs (3 approved, 1 experimental)
- Bone Diseases, Infectious
24 drugs (22 approved, 2 experimental)
- Bone Diseases, Metabolic
99 drugs (55 approved, 44 experimental)
- Bone Malalignment
- Bone Neoplasms
45 drugs (31 approved, 14 experimental)
- Bone Resorption
13 drugs (7 approved, 6 experimental)
- Coxa Magna
- Coxa Valga
- Eosinophilic Granuloma
11 drugs (9 approved, 2 experimental)
- Epiphyses, Slipped
- Genu Valgum
- Genu Varum
- Hyperostosis
- Osteitis
2 drugs (1 approved, 1 experimental)
- Osteitis Deformans
9 drugs approved
- Osteoarthropathy, Primary Hypertrophic
1 drug experimental
- Osteoarthropathy, Secondary Hypertrophic
- Osteochondritis
1 drug approved
- Osteochondrosis
1 drug approved
- Osteonecrosis
25 drugs (12 approved, 13 experimental)
- Spinal Diseases
70 drugs (53 approved, 17 experimental)
Drugs by status
Approved for this indication (8)
Phase 4 trials (16)
Phase 3 trials (22)
- metformin
- enclomiphene
- citalopram
- conjugated equine estrogens
- progesterone
- etanercept
- sertraline
- calcium
- menaquinone
- magnesium sulfate
- progestin
- reboxetine
- resveratrol
- collagen
- antihemophilic factor viii (Recombinant)
- autologous osteoblasts
- autologous mesenchymal stem cells
- soybean
- venlafaxine
- estrogen
- jmt103
- calcium phosphate
Phase 2 trials (12)
Phase 1 trials (15)
Organizations
Organization Involved with Phase 4 Indications (34)
- Amgen
- Roche
- Gilead Sciences
- Merck
- Novartis
- Bayer
- Cornell University
- Harvard University
- Federal University of Juiz de Fora
- Emory University
- Indiana University
- McGill University
- McMaster University
- Osaka University
- Stanley Dudrick's Memorial Hospital
- University of Southern Denmark
- Laval University
- Purdue University
- University of Calgary
- University of Copenhagen
- University of Vienna
- Pennsylvania State University
- University of Sao Paulo
- University of Barcelona
- Winthrop University
- University of Western Ontario
- Government of Canada
- The Japan Kidney Foundation
- Molecular Physiological Chemistry Laboratory, Inc.
- Higashikouri Hospital
- +4 more
Organization Involved with Phase 3 Indications (19)
- Daiichi Sankyo
- Baxalta
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- National Institute on Aging (NIA)
- University of Washington
- Guangzhou Medical University
- Ohio State University
- Oregon Health and Science University
- Wake Forest University
- Southern Medical University
- University of Turin
- Sun Yat-Sen University
- University of Texas, Galveston
- Society of Family Planning
- Government of Italy
Organization Involved with Phase 2 Indications (11)
Organization Involved with Phase 1 Indications (11)
Organization Involved with Other Experimental Indications (19)
- Shire
- Aarhus University
- DLR German Aerospace Center
- Northwestern University
- Ochsner Health System
- Providence Health & Services
- University of Kentucky
- University of Bologna
- University of Chester
- University of Chicago
- Université catholique de Louvain
- University of Trieste
- Hebrew University
- German Aerospace Centre
- University of Granada
- Orkla Health
- European Space Agency
- FNRS, Belgium
- The Heart Institute of Spokane